Otsuka Presents Final Phase 3 VISIONARY Results for VOYXACT in IgA Nephropathy at ASN Kidney Week 2026

Otsuka Pharmaceutical announced the final two-year results from the Phase 3 VISIONARY study for VOYXACT® (sibeprenlimab-szsi) in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression. Presented at the American Society of Nephrology (ASN) Kidney Week 2026 and simultaneously published in The New England Journal of Medicine, the data demonstrated that VOYXACT stabilized kidney function and reduced the risk of a composite kidney outcome event by 97.1% compared to placebo over two years. The treatment was also found to be safe and well-tolerated.